Cristina Csimma, Pharm. D., M.H.P.
Cristina Csimma was appointed a member of Idera’s Board of Directors in April 2019. Dr. Csimma has also served on the boards of directors of Syncona Partners since 2022 and Palisade Bio since 2021, and as the chair of the board of directors of Caraway Therapeutics since 2019, including as executive chair in 2019. Dr. Csimma is also on the advisory boards of the Muscular Dystrophy Association Venture Philanthropy Scientific Advisory Committee, the Harvard and Brigham and Women’s Hospital MRCT Center External Advisory Board, the TREAT-NMD Advisory Committee for Therapeutics (TACT), and the Executive Oversight Board to the National Institutes of Health (NIH) NeuroNext Network.
Dr. Csimma previously served as chair and executive chair of the board of directors of Forendo Pharma, and she was a director on the board of Seneca Biopharma until its merger with Leading BioSciences to form Palisade Bio. She has also served as a director on the boards of Juniper Pharmaceuticals and Vtesse, was the executive chair and a senior advisor of Exonics Therapeutics, and was President, founding CEO, and board director of Cydan. Dr. Csimma also served on the NIH Blueprint Neurotherapeutics Network External Oversight Committee, was Vice President of Drug Development at Virdante Pharmaceuticals Inc., Principal at Clarus Ventures, and held roles of increasing responsibility in Clinical Development and Translational Research at Wyeth, Genetics Institute, and Dana Farber Cancer Institute.
Dr. Csimma holds both a Doctor of Pharmacy and a Bachelor of Science in Pharmacy from the Massachusetts College of Pharmacy and Allied Health Sciences, as well as a Master of Health Professions from Northeastern University.